Lactobacillus paracasei NB23 for Muscle Mass and Metabolic Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sarcopenia and metabolic syndrome are limited, as there are no effective drugs available, and patients often struggle to adopt and maintain new exercise and eating habits.
Innovation Solution
The use of the Lactobacillus paracasei NB23 strain, a probiotic with physiological activities that promote muscle protein synthesis, enhance muscle cell proliferation and hypertrophy, resist inflammation and oxidation, and activate insulin-like growth factor 1 (IGF-1) pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If patients adopt new exercise and eating habits to treat sarcopenia, then muscle mass can be improved, but patient compliance and sustainability are poor
Solution Approach 1:
The patent introduces probiotics (Lactobacillus plantarum, Lactobacillus casei, Bifidobacterium animalis) as intermediary substances that mediate between diet and muscle protein synthesis. These probiotics activate the IGF-1/PI3K/Akt/mTOR pathway to promote muscle protein synthesis, providing a biological mediator that complements exercise and nutrition interventions while being easier to maintain compliance with through daily probiotic supplementation.
2Quantity of substance
If protein intake is increased to improve muscle mass, then muscle synthesis is enhanced, but metabolic burden increases
Solution Approach 1:
The patent changes the biochemical parameters of protein metabolism by introducing probiotics that activate the IGF-1/PI3K/Akt/mTOR signaling pathway. This pathway optimization allows for more efficient protein utilization and muscle protein synthesis at lower protein intake levels, thereby reducing the metabolic burden while maintaining or enhancing muscle mass building effectiveness.
3Productivity
If resistance training is extended in duration to improve muscle mass, then muscle synthesis increases, but time commitment and exercise intensity requirements increase
Solution Approach 1:
The patent implements continuous useful action through daily probiotic supplementation that continuously activates muscle protein synthesis pathways between exercise sessions. This continuous biochemical stimulation complements periodic resistance training, allowing for sustained muscle protein synthesis without requiring extended exercise duration or intensity, as the probiotics provide ongoing anabolic signaling.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Lactobacillus paracasei NB23 strain effectively increases muscle mass, improves muscle strength, and treats or prevents metabolic syndrome and related diseases by reducing inflammation, improving cardiovascular health, and regulating metabolic indicators.
Implementation Method 1
can activate insulin-like growth factor 1 (IGF-1) and insulin, thereby activating the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway in order to promote protein synthesis in muscle cells
Implementation Method 2
The Lactobacillus paracasei NB23 strain has the activity to inhibit nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and forkhead box protein-O (Fox-O) and can therefore prevent the degradation of muscle proteins or the apoptosis of muscle cells
Implementation Method 3
can prevent the degradation of muscle proteins or the apoptosis of muscle cells
Implementation Method 4
resist inflammation and oxidation
Data Source
AI summary
Disclosed herein are the Lactobacillus paracasei NB23 strain and a method of using the same to increase muscle mass and to prevent/treat metabolic syndrome. Administering an effective amount of the Lactobacillus paracasei NB23 strain or a metabolite thereof to an individual can effectively produce the effect of treating or preventing diseases associated with muscle loss or insufficient muscle mass, metabolic syndrome, and diseases related thereto.